< 1 minute read
Nov. 26, 2021
LYC-55716: An Oral RORγ Nuclear Receptor Agonist
LYC-55716
oral RORγ nuclear receptor agonist 450 mg BID, phase I/II, cancer from change in MoA of RORγ antagonist + opt. Journal of Medicinal Chemistry Lycera
Loading...
oral RORγ nuclear receptor agonist 450 mg BID, phase I/II, cancer from change in MoA of RORγ antagonist + opt. Journal of Medicinal Chemistry Lycera